Parrish K L, Tachibana M, Domer F R, Norris C H, Guth P S
Ann Otol Rhinol Laryngol. 1981 May-Jun;90(3 Pt 1):255-60. doi: 10.1177/000348948109000312.
The intrathecal administration of gentamicin has been used to treat bacterial meningitis. However, the influence of this route of administration on the well-known ototoxic activity of gentamicin is unknown. This route of administration should facilitate access to the inner ear and should increase the ototoxic liability. The possible ototoxic and neurotoxic effects of intrathecally administered gentamicin (0.5, 1, 2, 4, 6, 10 mg/day) in cats were evaluated. Hearing thresholds were obtained by a noninvasive technique prior to and on the 7th and 21st days after the initiation of a seven-day dosage regimen. Histological examination of the organ of Corti was routinely done. Additionally, the vestibular organs of one animal on the 4 mg/day regimen were examined. The concentrations of gentamicin in the cerebrospinal fluid were also determined. The data indicate that the 2 mg/day dose may be very close to the threshold dose for ototoxicity when gentamicin is given by intracisternal administration.
鞘内注射庆大霉素已被用于治疗细菌性脑膜炎。然而,这种给药途径对庆大霉素众所周知的耳毒性活性的影响尚不清楚。这种给药途径应便于药物进入内耳,并应增加耳毒性风险。评估了鞘内注射庆大霉素(0.5、1、2、4、6、10毫克/天)对猫可能产生的耳毒性和神经毒性作用。在开始为期七天的给药方案之前以及给药后第7天和第21天,通过无创技术获得听力阈值。常规对柯蒂氏器进行组织学检查。此外,还检查了一只接受4毫克/天给药方案的动物的前庭器官。还测定了脑脊液中庆大霉素的浓度。数据表明,当通过脑池内给药时,2毫克/天的剂量可能非常接近庆大霉素耳毒性的阈值剂量。